Bayer: Cheap Price, Heavy Debt - A Tactical Long with Clear Guardrails
Bayer remains a story of two forces: a depressed equity multiple driven by legacy acquisition debt and legal overhangs, and a diversified business with cash-generating pharma and crop-science franchises. We outline a mid-term tactical long with precise entry, target and stop-loss levels that balance upside from normalization with downside protectio…